Link to the University of Pittsburgh Homepage
Link to the University Library System Homepage Link to the Contact Us Form

Poly (A) binding protein cytoplasmic 1 is a novel co-regulator of the androgen receptor

Eisermann, K and Dar, JA and Dong, J and Wang, D and Masoodi, KZ and Wang, Z (2015) Poly (A) binding protein cytoplasmic 1 is a novel co-regulator of the androgen receptor. PLoS ONE, 10 (7).

[img]
Preview
PDF
Published Version
Available under License : See the attached license file.

Download (3MB)
[img] Plain Text (licence)
Available under License : See the attached license file.

Download (1kB)

Abstract

© 2015 Eisermann et al. The androgen receptor (AR) is a member of the steroid receptor superfamily that regulates gene expression in a ligand-dependent manner. The NTD of the AR plays a key role in AR transactivation including androgen-independent activation of the AR in castration-resistant prostate cancer (CRPC) cells. We recently reported that amino acids (a.a.) 50-250 of the NTD are capable of modulating AR nucleocytoplasmic trafficking. To further explore the mechanism associated with a.a. 50-250, GFP pull-down assays were performed in C4-2 CRPC cells transfected with GFP tagged a.a. 50-250 of the AR. Mass spectrometry analysis of the pulled down proteins identified poly (A) binding protein cytoplasmic 1 (PABPC1) interaction with this region of the AR. In silicoanalysis of gene expression data revealed PABPC1 up-regulation in prostate cancer tissue specimens and this up-regulation correlates to increased disease recurrence. Co-immunoprecipitation assays confirmed the association of PABPC1 with a.a. 50-250 of the NTD of the AR. Knockdown of PABPC1 decreased nuclear AR protein levels and inhibited androgen activation of the AR target PSA in LNCaP and C4-2 cells. Additionally, knockdown of PABPC1 inhibited transactivation of the PSA promoter by NAR (AR lacking the LBD) and attenuated proliferation of AR-positive prostate cancer cells. These findings suggest that PABPC1 is a novel co-regulator of the AR and may be a potential target for blocking activation of the AR in CRPC.


Share

Citation/Export:
Social Networking:
Share |

Details

Item Type: Article
Status: Published
Creators/Authors:
CreatorsEmailPitt UsernameORCID
Eisermann, K
Dar, JA
Dong, J
Wang, Ddaw112@pitt.eduDAW112
Masoodi, KZ
Wang, Zwangz2@pitt.eduWANGZ2
Contributors:
ContributionContributors NameEmailPitt UsernameORCID
EditorSaleem, MohammadUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Centers: Other Centers, Institutes, or Units > Pittsburgh Cancer Institute
Date: 15 July 2015
Date Type: Publication
Access Restriction: No restriction; Release the ETD for access worldwide immediately.
Journal or Publication Title: PLoS ONE
Volume: 10
Number: 7
DOI or Unique Handle: 10.1371/journal.pone.0128495
Institution: University of Pittsburgh
Schools and Programs: School of Medicine > Pharmacology and Chemical Biology
School of Medicine > Urology
Refereed: Yes
Date Deposited: 23 Aug 2016 14:21
Last Modified: 13 Oct 2017 22:58
URI: http://d-scholarship.pitt.edu/id/eprint/28420

Metrics

Monthly Views for the past 3 years

Plum Analytics

Altmetric.com


Actions (login required)

View Item View Item